canertinib has been researched along with paclitaxel in 1 studies
Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
---|---|---|---|---|---|
124 | 9 | 65 | 31,874 | 5,729 | 15,395 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bitran, JD; Burnett, D; Chiappori, AA; Eiseman, I; Ellis, PM; Hamm, JT; Lenehan, P; Lovalvo, J; Olson, S; Zinner, RG | 1 |
1 trial(s) available for canertinib and paclitaxel
Article | Year |
---|---|
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Odds Ratio; Paclitaxel; Patient Selection; Probability; Prognosis; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; United States | 2006 |